

Grzegorz W Basak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9028556/publications.pdf>

Version: 2024-02-01

120
papers

3,828
citations

186209

28
h-index

143943

57
g-index

123
all docs

123
docs citations

123
times ranked

4805
citing authors

#	ARTICLE	IF	CITATIONS
1	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	2.2	319
2	EBMT~NIH~CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. <i>Bone Marrow Transplantation</i> , 2018, 53, 1401-1415.	1.3	243
3	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	1.7	230
4	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. <i>Bone Marrow Transplantation</i> , 2021, 56, 1651-1664.	1.3	221
5	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	1.3	218
6	Fecal Microbiota Transplantation in Patients With Blood Disorders Inhibits Gut Colonization With Antibiotic-Resistant Bacteria: Results of a Prospective, Single-Center Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 364-370.	2.9	204
7	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020, 55, 126-136.	1.3	196
8	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. <i>Bone Marrow Transplantation</i> , 2020, 55, 2071-2076.	1.3	163
9	The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-Ts come into focus. <i>Bone Marrow Transplantation</i> , 2020, 55, 1604-1613.	1.3	147
10	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. <i>Bone Marrow Transplantation</i> , 2019, 54, 1575-1585.	1.3	129
11	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. <i>Bone Marrow Transplantation</i> , 2022, 57, 1217-1239.	1.3	119
12	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2018, 53, 1139-1148.	1.3	117
13	How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. <i>Blood Advances</i> , 2020, 4, 6283-6290.	2.5	89
14	Impact of Gut Colonization by Antibiotic-Resistant Bacteria on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective, Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1087-1093.	2.0	83
15	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. <i>Cancer</i> , 2017, 123, 2875-2880.	2.0	79
16	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 535-555.	1.3	75
17	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	1.3	61
18	Fecal Microbiota Transplantation Inhibits Multidrug-Resistant Gut Pathogens: Preliminary Report Performed in an Immunocompromised Host. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 255-258.	1.0	57

#	ARTICLE	IF	CITATIONS
19	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 662-673.	1.3	48
20	European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation. <i>Leukemia</i> , 2019, 33, 508-517.	3.3	45
21	Rapid resolution of COVID-19 after faecal microbiota transplantation. <i>Gut</i> , 2022, 71, 230-232.	6.1	44
22	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 228-241.	2.0	43
23	Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMTâ€“NCI Chronic GVHD Task Force. <i>Bone Marrow Transplantation</i> , 2014, 49, 49-54.	1.3	42
24	Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1786-1791.	2.0	42
25	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	1.3	39
26	Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. <i>European Journal of Haematology</i> , 2011, 86, 488-495.	1.1	34
27	Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients. <i>JAMA Oncology</i> , 2019, 5, 229.	3.4	33
28	Role of Physical Therapy before and after Hematopoietic Stem Cell Transplantation: White Paper Report. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e191-e198.	2.0	33
29	Variability of nutritional practices in peritransplant period after allogeneic hematopoietic stem cell transplantation: a survey by the Complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 1030-1037.	1.3	31
30	Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study. <i>Annals of Hematology</i> , 2019, 98, 2197-2211.	0.8	25
31	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e46-e54.	2.0	24
32	Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib. <i>Experimental Hematology</i> , 2014, 42, 439-447.	0.2	21
33	Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 2013-2019.	1.3	21
34	Fecal microbiota transplantation in patients with acute and chronic graft-versus-host diseaseâ€“spectrum of responses and safety profile. Results from a prospective, multicenter study. <i>American Journal of Hematology</i> , 2021, 96, E88-E91.	2.0	21
35	Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. <i>Haematologica</i> , 2022, 107, 1054-1063.	1.7	20
36	Accuracy and usability of the eGVHD app in assessing the severity of graft-versus-host disease at the 2017 EBMT annual congress. <i>Bone Marrow Transplantation</i> , 2018, 53, 490-494.	1.3	19

#	ARTICLE	IF	CITATIONS
37	Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 1022-1028.	1.3	19
38	Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model. <i>Oncology Reports</i> , 2008, 19, 1173-9.	1.2	18
39	2021 update of the 2012 ICSH Recommendations for identification, diagnostic value, and quantitation of schistocytes: Impact and revisions. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1264-1271.	0.7	17
40	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e145-e154.	2.0	16
41	Eosinophilic gastroenteritis and graft-versus-host disease induced by transmission of Norovirus with fecal microbiota transplant. <i>Transplant Infectious Disease</i> , 2021, 23, e13386.	0.7	15
42	Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 648-661.	1.3	14
43	Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: Multicenter Analysis by the Polish Adult Leukemia Group. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1833-1839.	2.0	14
44	The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis. <i>Bone Marrow Transplantation</i> , 2017, 52, 357-362.	1.3	13
45	4-1BBL-containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells. <i>Blood Advances</i> , 2022, 6, 1879-1894.	2.5	13
46	Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. <i>Bone Marrow Transplantation</i> , 2020, 55, 356-366.	1.3	12
47	Infectious Complications in Patients With Multiple Myeloma After High-Dose Chemotherapy Followed by Autologous Stem Cell Transplant: Nationwide Study of the Infectious Complications Study Group of the Polish Adult Leukemia Group. <i>Transplantation Proceedings</i> , 2020, 52, 2178-2185.	0.3	12
48	Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 632937.	2.2	12
49	Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 183-190.	1.3	12
50	Potent but transient immunosuppression of T-cells is a general feature of CD71+ erythroid cells. <i>Communications Biology</i> , 2021, 4, 1384.	2.0	12
51	Incidence of Adenoviral DNAemia in Polish Adults Undergoing Allogeneic Haematopoietic Stem Cell Transplantation. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2015, 63, 79-84.	1.0	11
52	Kidney dysfunction after hematopoietic cell transplantation—Etiology, management, and perspectives. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 195-205.	0.6	11
53	Incidence of Acute Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation over Time: A Study from the Transplant Complications and Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2018, 132, 2120-2120.	0.6	11
54	The Role of Fecal Microbiota Transplantation in the Treatment of Acute Graft-versus-Host Disease. <i>Biomedicines</i> , 2022, 10, 837.	1.4	11

#	ARTICLE	IF	CITATIONS
55	Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland. <i>Medical Science Monitor</i> , 2019, 25, 305-311.	0.5	10
56	Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT â€” A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party. <i>Frontiers in Immunology</i> , 2020, 11, 586.	2.2	10
57	Advances in Intestinal Barrier Preservation and Restoration in the Allogeneic Hematopoietic Cell Transplantation Setting. <i>Journal of Clinical Medicine</i> , 2021, 10, 2508.	1.0	10
58	Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroidâ€”refractory/dependent acute, gastrointestinal graftâ€”versusâ€”host disease: A case series. <i>American Journal of Hematology</i> , 2021, 96, E461-E463.	2.0	10
59	Szczepienia ochronne u chorych dorosÅ¸ych po przeszczepieniu komÃ³rek krwiotwÃ³rczych â€” zalecenia sekcji do spraw zakaÅ¸eÅ¸, PALG. <i>Acta Haematologica Polonica</i> , 2017, 48, 1-9.	0.1	9
60	Azacitidine for Relapse After Allogeneic Stem Cell Transplantationâ€”Single-Center Study. <i>Transplantation Proceedings</i> , 2018, 50, 2212-2217.	0.3	8
61	Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. <i>Haematologica</i> , 2018, 103, 1843-1852.	1.7	8
62	Pure Red Cell Aplasia Related to Parvovirus B19 Infection in Simultaneous Pancreas and Kidney Recipient: A Case Report. <i>Transplantation Proceedings</i> , 2020, 52, 2539-2543.	0.3	8
63	Leukaemia cutis for clinicians, a literature review. <i>Postepy Dermatologii I Alergologii</i> , 2021, 38, 359-365.	0.4	8
64	Pericarditis in Patients With Chronic Graft-vs-Host Disease. <i>Transplantation Proceedings</i> , 2018, 50, 2218-2222.	0.3	7
65	Chemotherapy During Active SARS-CoV2 Infection: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2021, 11, 662211.	1.3	7
66	Analysis of the shedding of three Î²-herpesviruses DNA in Polish patients subjected to allogeneic hematopoietic stem cell transplantation: Six-year follow up. <i>Journal of Clinical Virology</i> , 2016, 76, 30-35.	1.6	6
67	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2019, 54, 2060-2071.	1.3	6
68	EQ-5Dâ€”Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review. <i>Value in Health</i> , 2020, 23, 953-968.	0.1	6
69	What Model of Nutrition Can Be Recommended to People Ending Their Professional Sports Career? An Analysis of the Mediterranean Diet and the CRON Diet in the Context of Former Athletes. <i>Nutrients</i> , 2020, 12, 3604.	1.7	6
70	Haematological disorders following kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 409-420.	0.4	6
71	Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group. <i>Journal of Clinical Apheresis</i> , 2021, 36, 443-453.	0.7	6
72	BCR/ABL Kinase Inhibits Mismatch Repair To Reduce Apoptosis and Induce Point Mutations.. <i>Blood</i> , 2007, 110, 32-32.	0.6	6

#	ARTICLE	IF	CITATIONS
73	Gut Colonization by Multidrug-Resistant Gram-Negative Bacteria Is an Independent Risk Factor for Development of Intestinal Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1221-1222.	2.0	5
74	Infections due to alphaherpesviruses in early post-transplant period after allogeneic haematopoietic stem cell transplantation: Results of a 5-year survey. <i>Journal of Clinical Virology</i> , 2017, 87, 67-72.	1.6	5
75	Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation – a prospective, non-interventional study of the EBMT Transplant Complication Working Party. <i>Haematologica</i> , 2020, 105, 1977-1983.	1.7	5
76	The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation. <i>Blood</i> , 2015, 126, 480-480.	0.6	5
77	Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 335.e1-335.e17.	0.6	5
78	Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1642-1646.	1.3	4
79	Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis. <i>European Journal of Haematology</i> , 2021, 107, 129-136.	1.1	4
80	The Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias. <i>Frontiers in Oncology</i> , 2021, 11, 741376.	1.3	4
81	How can an internal medicine specialist save a patient with hemophagocytic lymphohistiocytosis (HLH)? <i>Polish Archives of Internal Medicine</i> , 2020, 130, 431-437.	0.3	4
82	Ice-cream used as cryotherapy during high-dose melphalan conditioning reduces oral mucositis after autologous hematopoietic stem cell transplantation. <i>Scientific Reports</i> , 2021, 11, 22507.	1.6	4
83	Plasmapheresis improves chronic fatigue in patients with primary biliary cholangitis. <i>Polish Archives of Internal Medicine</i> , 2020, 131, 205-207.	0.3	4
84	Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation – study on behalf of CMWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 633-640.	1.3	4
85	The Role of the Crosstalk Between Gut Microbiota and Immune Cells in the Pathogenesis and Treatment of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2022, 13, 853540.	2.2	4
86	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3541.	1.0	4
87	Management of growth failure and growth hormone deficiency after pediatric allogeneic HSCT: Endocrinologists are of importance for further guidelines and studies. <i>Pediatric Hematology and Oncology</i> , 2019, 36, 494-503.	0.3	3
88	Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients – results of the PALG study – PolAZA™. <i>Hematology</i> , 2021, 26, 556-564.	0.7	3
89	Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. <i>Frontiers in Immunology</i> , 2020, 11, 613954.	2.2	3
90	IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. <i>Scientific Reports</i> , 2021, 11, 10017.	1.6	3

#	ARTICLE	IF	CITATIONS
91	Impact of decontamination therapy on gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic cell transplantation in children. <i>Current Research in Translational Medicine</i> , 2021, 69, 103298.	1.2	3
92	Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation – a single-center analysis. <i>Annals of Hematology</i> , 2021, 100, 3007-3016.	0.8	3
93	A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA+ HR-MDS (SELECT-MDS-1).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7075-TPS7075.	0.8	3
94	Relation of the polymorphism of cyp51A sequence and the susceptibility of <i>Aspergillus fumigatus</i> isolates to triazoles determined by commercial gradient test (Etest) and by reference methods. <i>Acta Biochimica Polonica</i> , 2017, 64, 631-634.	0.3	2
95	Multimodal Approach to Assessment of Fecal Microbiota Donors based on Three Complementary Methods. <i>Journal of Clinical Medicine</i> , 2020, 9, 2036.	1.0	2
96	IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 686-693.	0.2	2
97	Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 3084-3087.	1.3	2
98	Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients – study of Infectious Diseases Working Party of EBMT. <i>Journal of Infection</i> , 2021, , .	1.7	2
99	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1150-1163.	1.3	2
100	Practice patterns in chronic graft-versus-host disease patient management and patient reported outcome measures across the EBMT allogeneic transplantation network. <i>Bone Marrow Transplantation</i> , 2022, 57, 1458-1460.	1.3	2
101	Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria. <i>Bone Marrow Transplantation</i> , 2018, 53, 417-421.	1.3	1
102	Sequence typing of human adenoviruses isolated from Polish patients subjected to allogeneic hematopoietic stem cell transplantation – a single center experience. <i>Hematology</i> , 2018, 23, 633-638.	0.7	1
103	Seasonal variation of human physiology does not influence the harvest of peripheral blood CD34+ cells from unrelated hematopoietic stem cell donors. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102917.	0.5	1
104	Pseudoneutropenia as a factor-limiting access to chemotherapy for cancer patients: the effect of a simple meal. <i>Supportive Care in Cancer</i> , 2021, 29, 3767-3771.	1.0	1
105	Allogeneic Hematopoietic Stem Cell Transplantation Is Feasible After Solid Organ Transplantation: A Retrospective Analysis By The Early Complications Subcommittee Of The Complications and Quality Of Life Working Party, EBMT. <i>Blood</i> , 2013, 122, 2110-2110.	0.6	1
106	Conditioning Intensity Does Not Influence the Outcome of Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome. a Joint Study By the Polish Adult Leukemia Group and the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 2564-2564.	0.6	1
107	Provision of Long-Term Monitoring and Late Effects Services Following Hematopoietic Cell Transplantation (HCT): A Survey of European Programs By the Complications and Quality of Life Working Party of the EBMT. <i>Blood</i> , 2016, 128, 4607-4607.	0.6	1
108	Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report. <i>Transplantation Proceedings</i> , 2020, 52, 2548-2550.	0.3	0

#	ARTICLE	IF	CITATIONS
109	Electrophysiological Procedures in Patients With Coagulation Disorders—A Systemic Review • Circulation Journal, 2020, 84, 875-882.	0.7	0
110	Salvage autologous hematopoietic stem cell transplantation for multiple myeloma performed with stem cells procured after previous high dose therapy • a multicenter report by the Polish Myeloma Study Group. Leukemia and Lymphoma, 2021, 62, 3226-3234.	0.6	0
111	Late Post-Operative Occurrence of Dentin Hypersensitivity in Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation—A Preliminary Report. International Journal of Environmental Research and Public Health, 2021, 18, 8761.	1.2	0
112	BCR/ABL Kinase Disrupts Formation of Mismatch Repair Complex To Induce Genomic Instability.. Blood, 2005, 106, 2864-2864.	0.6	0
113	Potential of the Antileukemic Effects of Imatinib through the Modulation of BCRP/ABCG2 Activity.. Blood, 2010, 116, 3400-3400.	0.6	0
114	Investigation and Management of Bone Mineral Density Following Hematopoietic Cell Transplantation: A Survey of Current Practice by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1955-1962.	2.0	0
115	Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party. Blood, 2021, 138, 1809-1809.	0.6	0
116	Management of Steroid-Refractory Graft-Versus-Host Disease - a Survey By the Transplant Complications Working Party of the EBMT. Blood, 2021, 138, 2884-2884.	0.6	0
117	Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group. Blood, 2020, 136, 36-37.	0.6	0
118	Impact of pre-transplantation sinus abnormalities assessed by Lund-Mackay scoring system on sinusitis occurrence after allogeneic hematopoietic cell transplantation in acute leukemia patients. Folia Medica Cracoviensia, 2021, 61, 109-120.	0.3	0
119	Chronic Kidney Disease in Patients After Allogeneic Hematopoietic Cell Transplant. Transplantation Proceedings, 2022, , .	0.3	0
120	Increase Urinary Biomarkers of Kidney Injury in Patients After Allogenic Hematopoietic Stem Cell Transplant Reflect Kidney Damage Even in Normal Kidney Function. Transplantation Proceedings, 2022, 54, 1141-1144.	0.3	0